Close this search box.
Subscriber Log In

Themes from BIO Europe


There’s far too much to share in one blog post, but there were three areas that I wanted to summarise as I think they’re a good indicator of the current state of the biopharma market and give us an insight into what we can expect from pharma and biotech in 2024. 1. Dealmaking Increasing competition […]

Quick View: Biopharma Dealmaking in Q3


The first half of the year showed some promise. Did the third quarter continue the trend? Well… If you read our round up of the state of the biopharma market at the halfway point of the year, you may have come away with, if not a spring in your step, then a least a little […]

Late to the Party? Prepare to Pay the Price


I saw a tweet recently asking “in recent years, what has become simultaneously worse and more expensive?”. One wag responded with “life”, but I’d also argue that investing in biopharma companies is a feasible answer. Bear with me. Before the recent slump put a downer on the markets, public and private investors had been backing […]